Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Income: 2022-2025

Historic Net Income for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to -$20.8 million.

  • Orchestra BioMed Holdings' Net Income fell 35.02% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 33.72%. This contributed to the annual value of -$60.9 million for FY2024, which is 27.88% down from last year.
  • Orchestra BioMed Holdings' Net Income amounted to -$20.8 million in Q3 2025, which was down 7.57% from -$19.4 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Net Income ranged from a high of -$5.1 million in Q1 2022 and a low of -$20.8 million during Q3 2025.
  • In the last 3 years, Orchestra BioMed Holdings' Net Income had a median value of -$15.4 million in 2024 and averaged -$15.4 million.
  • Data for Orchestra BioMed Holdings' Net Income shows a maximum YoY slumped of 125.14% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Net Income stood at -$9.8 million in 2022, then declined by 15.72% to -$11.4 million in 2023, then slumped by 42.05% to -$16.2 million in 2024, then slumped by 35.02% to -$20.8 million in 2025.
  • Its Net Income stands at -$20.8 million for Q3 2025, versus -$19.4 million for Q2 2025 and -$18.8 million for Q1 2025.